Bolt Biotherapeutics Reports Improved Q3 Loss of $7.1 Million, Announces New Restructuring Plan

Bolt Biotherapeutics, Inc. reported its financial results for the third quarter and nine months ended September 30, 2025, revealing a net loss of $7.1 million for the quarter, a significant improvement from the $15.2 million loss recorded in the same period of 2024. For the nine-month period, the company reported a net loss of $26.7 million, down from $47.2 million in the prior year. Collaboration revenue for the third quarter increased to $2.2 million, compared to $1.1 million in the same quarter last year, while total revenue for the nine months decreased to $5.2 million from $7.7 million, primarily due to revenue recognized under the Amended Innovent Agreement in 2024.

Operating expenses for the third quarter were $9.9 million, a decrease from $17.6 million in the prior year, driven by reduced research and development costs, which fell to $6.5 million from $13.8 million. This reduction is attributed to a workforce reduction of approximately 50% and the discontinuation of the development of trastuzumab imbotolimod. General and administrative expenses also decreased to $3.3 million from $3.8 million, reflecting lower personnel-related costs due to the restructuring plan. The company did not incur any restructuring charges in the latest quarter, contrasting with $3.6 million in charges recorded in the nine months ended September 30, 2024.

As of September 30, 2025, Bolt Biotherapeutics had total assets of $65.1 million, down from $99.6 million at the end of 2024. The company’s cash and cash equivalents increased to $17.8 million from $7.2 million, while total liabilities decreased to $32.9 million from $42.4 million. The accumulated deficit stood at $454.1 million, reflecting the ongoing challenges faced by the company in achieving profitability. The company’s cash position is expected to fund operations into 2027, although there is substantial doubt about its ability to continue as a going concern without raising additional capital.

Strategically, Bolt Biotherapeutics has focused on its clinical-stage pipeline, particularly the development of its Boltbody ISAC platform and the BDC-3042 program, which targets claudin 18.2. The company has also established a wholly-owned subsidiary in Australia to enhance its global footprint. However, the company announced a new restructuring plan on October 1, 2025, which will further reduce its workforce by approximately 50% to preserve cash. This restructuring is expected to incur pre-tax charges of $1.5 million to $2.0 million, primarily related to severance payments.

Looking ahead, Bolt Biotherapeutics anticipates continued operating losses as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company remains focused on its collaborations with Toray, Genmab, and Innovent, which are expected to contribute to its revenue stream. However, the company acknowledges the inherent risks and uncertainties in drug development and the need for additional capital to support its operations and growth initiatives.